BioVie Inc. (BIVIW)

Market Cap	11.90M
Revenue (ttm)	n/a
Net Income (ttm)	-17.91M
Shares Out	7.53M
EPS (ttm)	-12.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,454
Open	0.4500
Previous Close	0.4320
Day's Range	0.4320 - 0.4503
52-Week Range	0.3000 - 0.5000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2025

About BIVIW

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: BIVIW
• Website: https://bioviepharma.com